Autopsy report · NCT00488059

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients

“This study was terminated early due to poor enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 4 months before it stopped.
• 29 participants enrolled.
• Results were posted on the registry 2 years 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Hoffmann-La Roche

Sponsor type

Industry

Conditions

HIV Infections

Interventions

enfuvirtide [Fuzeon]; Optimized background ARV; Integrase inhibitor; enfuvirtide [Fuzeon]

Participants

29

Sites

43

Countries

Puerto Rico, United States

Trials that died the same way

• Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
  “the study was terminated early due to poor enrollment” (98% match in meaning)
• A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
  “Due to low enrollment, this study was terminated early.” (97% match in meaning)
• MIRACLE EF Clinical Study
  “The study was terminated early due to low enrollment.” (96% match in meaning)
• The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
  “This study was prematurely terminated due to low enrollment” (95% match in meaning)
• Use of Teriparatide to Accelerate Fracture Healing
  “The study was terminated due to poor enrollment.” (95% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.